Proteomics

Dataset Information

0

The changes in HNSCC cell lines (e.g., CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main acetylation sites in resistance cell lines. In this study, it was found that the acetylation of STAT1 might hinder the downstream signaling of IFN-γ

ABSTRACT: Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the acetylation sites in wild-type and resistant cells. We proposed that the acetylation of STAT1 may impair IFN-γ response.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Po-Hsien Chiu  

LAB HEAD: Muh-Hwa Yang

PROVIDER: PXD054332 | Pride | 2025-12-29

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20220907-A0732-9_90uL-Lys-C-4-2.mzML Mzml
20220907-A0732-9_90uL-Lys-C-4-2.mzid.gz Mzid
20220907-A0732-9_90uL-Lys-C-4-2.raw Raw
CETUXIMABACETYL00001.sdrf.tsv Tabular
checksum.txt Txt
Items per page:
1 - 5 of 5
altmetric image

Publications

Sequential cancer therapy presents a critical challenge, as the impact of prior treatments on immunotherapy remains unclear. Here, we demonstrate that therapeutic stress from prolonged cetuximab exposure induces tumor-intrinsic resistance to immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC). In a multicenter analysis, extended cetuximab treatment correlates with poor ICB response and survival. Mechanistically, chronic therapeutic stress provokes an initial inflamm  ...[more]

Similar Datasets

Proteomics The changes in cetuximab resistant HNSCC cell lines (e.g., OECM1-cetuximabR and CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main phosphorylation sites in resistance cell lines.
2025-12-29 | PXD054186 | Pride
Proteomics The changes in HNSCC cell lines (e.g., OECM1) when treated with Cetuximab (500 ug/ml) at different passages. We used LC-MS/MS to identify the main target pathway. These findings could significantly enhance our evidence.
2025-12-29 | PXD054113 | Pride
Transcriptomics Genes expression in the different passages of OECM-1 cell line received cetuximab
2025-12-30 | GSE264007 | GEO
Transcriptomics Mitochondrial fatty acid oxidation regulates monocytic type I interferon signaling via histone acetylation.
2025-01-07 | GSE279878 | GEO
Proteomics PX-12 Modulates Vorinostat-induced acetylation and methylation marks in CAL 27 cells
2025-05-07 | PXD053244 | Pride
Transcriptomics Expression Profiling on Human Cell Lines with Different Acetylation Levels
2014-08-06 | E-GEOD-49640 | biostudies-arrayexpress
Transcriptomics Expression data of the cetuximab-resistant head and neck squamous cell lines and the parental cell lines.
2019-05-14 | GSE131108 | GEO
Transcriptomics Expression Profiling on Human Cell Lines with Different Acetylation Levels
2014-08-06 | GSE49640 | GEO
Transcriptomics Transcription profiling of Arabidopsis treated with Histone acetylation during seed germination (GEO Super Series)
2008-06-12 | E-GEOD-3799 | biostudies-arrayexpress
Clinical Protein acetylation as a diet-modifiable biomarker of colorectal cancer risk
| 2425832 | ecrin-mdr-crc